ReviewFrontiers in cell and developmental biology2025
Aging-associated mechanisms and metabolic vulnerabilities in esophageal carcinoma: an integrative review.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GRP78 dysregulation: A proposed molecular mechanism linking the tumor microenvironment to sepsis susceptibility in patients with cancer (Review).International journal of molecular medicine · 2026Review
- Exploring the prognostic role of senescence-related genes in gastric cancer through multi-omics integration and machine learning.Human genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma (EC), comprising esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC), remains a deadly malignancy predominantly affecting individuals over 60 years of age. Although advances in diagnosis and treatment have improved outcomes for some cancers, EC still carries a poor prognosis, particularly in the elderly. Aging contributes significantly to EC pathogenesis via accumulated genetic mutations, metabolic deregulation, immunosenescence, and a pro-tumorigenic microenvironment. In this review, we synthesize current understanding of the molecular alterations that drive EC, with particular emphasis on age-related factors. We examine key genomic mutations (e.g., TP53, chromosomal instability), metabolic reprogramming (including glycolysis, glutaminolysis, and lipid metabolism), and their interplay with the tumor microenvironment (TME). We also highlight the influence of aging processes such as clonal hematopoiesis, senescence-associated secretory phenotype (SASP), and immune exhaustion in modulating tumor behavior and therapeutic resistance. We propose that aging-associated metabolic and immunologic alterations represent promising targets for therapeutic intervention. Greater integration of aging biology into EC research and clinical strategy is needed to advance personalized care for elderly patients. This review provides a conceptual foundation for future translational and clinical studies at the intersection of oncology and aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.